Research programme: anti-botulinum neurotoxin monoclonal antibodies - MorphotekAlternative Names: Botulinum neurotoxin therapeutics - Morphotek
Latest Information Update: 13 Apr 2011
At a glance
- Originator Morphotek
- Class Monoclonal antibodies
- Mechanism of Action Botulinum toxin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Botulism
Most Recent Events
- 26 Sep 2008 Morphotek Inc enter into an agreement to access Pivotal BioScience's LEC platform technology for the development of therapeutic monoclonal antibodies
- 20 Sep 2007 Early research in Botulism in USA (Parenteral)